Repository logo
 

Investigating the chromatin dynamics that underlie CRISPRi-validated enhancer-promoter interactions


Type

Thesis

Change log

Authors

Pirvan, Liviu 

Abstract

Discovered in the 1980s, enhancers have grown to become important cis-regulatory elements responsible for both temporal and tissue-specific gene regulation coordinating cell differentiation processes, pathological responses and disease progression, and cellular functions in normal physiological states. However, due to their complex nature and function, research into enhancer activity remains highly active, producing novel insights based on multiple types of data and experimental assays. Firstly, advances in Next Generation Sequencing technologies in the 2000s allowed extensive enhancer characterisations through mass detection of genome wide epigenetic marks, chromatin conformation, chromatin accessibility, and expression data. Nevertheless, the process of validating enhancer targets remained costly until recent developments of CRISPRi methods enabled large scale perturbation experiments for identifying the target genes of enhancers. However, CRISPRi methods produced results that were not always consistent with the previous understanding of enhancer-promoter interactions (EPIs), raising questions regarding the mechanism by which EPIs are produced.

Then, this thesis aims to investigate the ways by which chromatin dynamics enable the function of CRISRPi-validated EPIs, in order to explain the discrepancies observed. Firstly, using experimental data from mouse cells, I consider EPIs based on chromatin folding data while highlighting the limitations of current frameworks. Then, I consider more complex representations of biological features to propose predictive models for improving EPI detection. Next, to investigate the chromatin dynamics that underlie CRISPRi-validated EPIs, I use unsupervised machine learning to identify distinct biological classes of EPIs that show mechanistic differences. With respect to these classes, I propose that they are underlied by different chromatin structures, and their functions may be related to enabling cancer progression. Thus, the former insight motivates the development of a graph-based deep learning model that can model complex chromatin structures and transcription factor binding data in order to predict EPIs and interpret their structures. Similarly, the second insight motivates the design of a CRISPRi experiment that can be used to validate the classification system in a second independent cell type. Then, I conclude that the relationship between the functions of CRISPRi-validated EPIs and chromatin dynamics reveals novel complexities that can be modelled computationally to describe important processes in gene regulation.

Description

Date

2023-01-30

Advisors

Basu, Srinjan

Keywords

gene regulation

Qualification

Doctor of Philosophy (PhD)

Awarding Institution

University of Cambridge
Sponsorship
Medical Research Council (2118074)
This work was supported by the UK Medical Research Council doctoral training award. Pilot MCF7 cell proliferation assays were performed by Dr. Inma Spiteri (supervised by Dr. Shamith Samarajiwa - funded by Cancer Research UK) The MCF7 experiment was funded by the UK Medical Research Council funding (MC UU 12022/10) provided to Dr. Shamith Samarajiwa’s laboratory at the MRC Cancer Unit. Execution of the experiments was carried out in collaboration with Dr. Srinjan Basu and Maike Paramor from the Wellcome-MRC Cambridge Stem Cell Institute, who performed the Hi-C experiments; Dr. George Gentsch and Dr. Alasdair Russell from the CRUK Cambridge Institute, who performed the TAP-seq experiment; cells were grown, harvested and treated by Robert Hanson, and Dr. Tanmay Gupta, supervised by Dr. Charlie Massie from Early Cancer Institute; the sequencing for ChIP-seq, RNA-seq, and ATAC-seq was performed by Active Motif; and Hi-C sequencing was carried out by the CRUK Cambridge Institute Genomics Core Facility. I am grateful for their generosity to help even during the harsh conditions inflicted by the COVID-19 pandemic. Additional data used in my investigations was kindly provided Dr. Marco Sciacovelli and Dr. Connor Rogerson from Christian Frezza’s group at the MRC Cancer Unit and by Dr. Srinjan Basu and Maike Steindel at Wellcome-MRC Cambridge Stem Cell Institute.